Jazz Pharmaceuticals (JAZZ) FY2013 results: revenue $872 million, up 48.9% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $872 million for fiscal 2013, the year ended 31 December 2013, up 48.9% on the year before. Net income was $216 million, down 25.0%, and diluted earnings per share $3.51. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2014.
Revenue
$872 million
+48.9% on the year
FY2009FY2013
Operating margin
39.0%
33.8% a year earlier
FY2009FY2013
Net income
$216 million
-25.0% on the year
FY2009FY2013
Diluted EPS
$3.51
-26.7% on the year
FY2009FY2013
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Revenue
872
586
272
+48.9%
Research and development
41.6
20.5
14.1
+103.3%
Selling, general and administrative
304
224
109
+35.9%
Operating income
340
198
128
+72.0%
Operating margin
39.0%
33.8%
46.9%
Interest expense
n/a
n/a
1.7
Pre-tax income
308
177
125
+73.6%
Income tax
91.6
-83.8
0.0
Effective tax rate
29.8%
-47.2%
0.0%
Net income
216
289
125
-25.0%
Net margin
24.8%
49.2%
45.9%
Diluted EPS
$3.51
$4.79
$2.67
-26.7%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Operating cash flow
288
250
152
+15.5%
Capital expenditure
10.0
6.0
1.3
+66.9%
Free cash flow
278
244
150
+14.2%
Free cash flow margin
31.9%
41.6%
55.2%
Cash from investing
-16.3
-395
-81.2
Cash from financing
-23.9
449
-33.1
Depreciation and amortisation
82.1
74.2
7.8
+10.6%
Share-based compensation
44.6
23.0
20.7
+93.6%
Buybacks
136
0.0
0.0
Diluted shares, weighted
62m
60m
47m
+2.3%
Shares outstanding at period end
58m
58m
42m
-0.3%
Balance sheet
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Shareholders' equity
1,296
1,121
193
+15.5%
Non-controlling interest
0.0
n/a
n/a
Debt
550
457
0.0
+20.4%
Other liabilities
393
388
60.8
+1.1%
Total liabilities and equity
2,238
1,966
254
+13.8%
Fixed assets
14.2
7.3
1.6
+95.7%
Goodwill
450
443
38.2
+1.8%
Intangible assets
812
870
14.6
-6.6%
Investments
n/a
0.0
75.8
Cash and equivalents
637
387
82.1
+64.4%
Receivables
125
75.5
34.4
+65.3%
Inventory
28.7
26.5
3.9
+8.1%
Other assets
171
157
3.0
+8.7%
Total assets
2,238
1,966
254
+13.8%
10-K for the year ended 31 December 2013, filed 25 February 2014: the filing.